source
- #ERS26: Beam says AATD base editing data hold up after one yearBeam Therapeutics on Tuesday shared additional data from an early-stage trial of its gene therapy candidate in a rare disease that causes lung and liver damage. In six patients in a Phase 1/2 study…Endpoints · 45m ago↗ source
- Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drugIn the wake of its high-profile setback in heart disease late last week, Novartis really needed a win. It didn’t get one. The Swiss pharma said Tuesday that in a late-stage ...Endpoints · 50m ago↗ source
- Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 testThe phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Bioscien…